Tetra Bio-Pharma Inc. announced results from a study of Onternabez and Favipiravir against ARDS acute respiratory distress syndrome sepsis, and COVID 19 through PREPAiRE, an AI powered platform that integrates target identification, validation, lead discovery optimization, drug synthesis, and preclinical testing.
Results from the study show that Tetra's investigational therapeutic, ARDS 003, which contains the active pharmaceutical ingredient Onternabez, acts against various ARDS and sepsis targets such as IL 6 and IL 8. In various targets of inflammatory conditions, onternabez plays an important role in mitigating the inflammatory response.
Favipiravir works against different SARS-CoV-2 targets, such as spike glycoprotein and nucleoprotein. The interaction between Favipiravir and Onternabez against SARS-COV-2 results in a positive molecule synergy probability that is considered significant and justifys the combination of the two drugs to create a new therapeutic that is expected to be beneficial to the treatment efficacy and to reduce the duration of the disease. The source of infection can be controlled by favipiravir. Onternabez would contribute to the antiviral efficacy and can control the result of the infection i.e. Guy Chamberland, CEO and chief regulatory officer at Tetra, said We are very pleased with these artificial intelligence results as well as the recent positive results from the PIONEER trial. This underscores our commitment with Cellvera to developing an innovative combination drug candidate for fighting viral diseases. We are more excited about our collaboration with Cellvera and the possibility of delivering the next scientific breakthroughs. According to the IUPHAR BPS Guide to Pharmacology, Onternabez is a form of synthetic cannabinoid that acts as a CB receptor agonist and has anti-inflammatory activity. Recent research has shown that natural cannabinoids can be effective against COVID 19 too. Cannabinoid acids in hemp cannabigerolic acid, or CBGA, and cannabidiolic acid, also known as CBDA have the ability to bind to the SARS-CoV-2 spike protein that causes COVID 19 These acids can block the virus from reaching into cells and causing infection by binding to the spike protein.
Get your daily dose of cannabis news on Benzinga Cannabis. Tetra Bio-Pharma Announces the Second Closing of Financing With Alpha Blue Ocean